Sign Out
Lenangio as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
Lenangio in combination with dexamethasone is indicated for the treatment of previously untreated multiple myeloma patients who are not eligible for transplant.
Lenangio in combination with dexamethasone is indicated for the treatment of multiple myeloma in patients who have received at least one prior therapy.
